View all the latest information in myeloproliferative neoplasms, arranged by trials and clinical studies. Listed below are recently added trial updates.
Editorial Theme | The management of relapsed/refractory myelofibrosis: Part 4 – investigational combination approaches
The unmet clinical need in treating patients with relapsed or refractory...
What do the preliminary results of the MANIFEST trial say about CPI-0610 in treating MF?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to...
Reviewing the safety of JAK inhibitors for the treatment of myelofibrosis
Over the past decade, seminal studies have led to the identification of specific driver mutations in the pathogenesis of...
Clinical factors associated with response to ruxolitinib in patients with myelofibrosis
A dysregulated Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is...
Essential thrombocythemia is associated with a higher risk of thrombosis during COVID-19
COVID-19 has been reported to damage multiple organ systems, primarily the respiratory system, which...
Withdrawal of ruxolitinib increases risk of mortality in patients with myelofibrosis and COVID-19
Outcomes of coronavirus 2019 disease (COVID-19) in patients with MPN are still not fully understood...
Editorial theme | The management of relapsed/refractory myelofibrosis: Part 3 – treatment options beyond JAK inhibition
There is an ongoing effort to develop novel approaches with different modes of...
IMbark phase II study of imetelstat for R/R myelofibrosis: Updates from ASH 2020
Although Janus kinase (JAK) inhibition provides symptomatic relief for patients with myelofibrosis (MF), it does not...